Pluri Inc (prev Pluristem)

3D cell expansion, placenta-derived cell therapy, cell-based manufacturing

replacementreplacingcell therapy

pluri-biotech.com·Israel; Brazil·Founded 2003·Public

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-TEIJ

Summary · Eternal Search editorial

Pluri Inc (prev Pluristem) 3D cell expansion, placenta-derived cell therapy, cell-based manufacturing

Pluri uses patented three-dimensional cell expansion platforms to grow plant, animal and human cells in an efficient and cost-effective process. Its health pipeline includes PLX-PAD and PLX-R18 placenta-derived, mesenchymal-like adherent stromal cell products. The company also applies its platform beyond pharma, including food tech, agri-tech and CDMO services.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite12

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Pluri Inc (prev Pluristem) — Near-term readout · Bottom quartile. Derived deterministically from 11 extracted project(s). Most-advanced status: phase 3. Band: near_readout. Aging-relevance not LLM-reviewed in this pass.

Source: Deterministic

At a glance

Webpluri-biotech.com

HQIsrael; Brazil

Founded2003

StagePublic

Publications

26 on file

012025Cocaine-Induced Microglial Impairment and Its Rehabilitation by PLX-PAD Cell Therapy—→

022025Development of PLX-R18, a promising and novel countermeasure for radiation-associated injuries.Drug discovery today→032025Development of PLX-R18, a Promising and Novel Countermeasure for Radiation-Associated Injuries—→042025AACR-IO: Advancing the Allogeneic MAIT Platform for Targeting Solid Tumors—→052025Correction: Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.Bone marrow transplantation→062024PACE: randomized, controlled, multicentre, multinational, phase III study of PLX-PAD for critical limb ischaemia in patients unsuitable for revascularization: randomized clinical trial—→072023Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study.Bone marrow transplantation→082023Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study—→092022Intramuscular and intratendinous placenta-derived mesenchymal stromal-like cell treatment of a chronic quadriceps tendon rupture—→102022Placenta-Derived Mesenchymal-like Adherent Stromal Cells as an Effective Cell Therapy for Cocaine Addiction in a Rat Model.Pharmaceutics→112022Placenta-Derived Mesenchymal-like Adherent Stromal Cells as an Effective Cell Therapy for Cocaine Addiction in a Rat Model—→122022A functional corona around extracellular vesicles enhances angiogenesis, skin regeneration and immunomodulation—→132022Pre-Administration of PLX-R18 Cells Protects Mice from Radiation-Induced Hematopoietic Failure and Lethality.Genes→142022Pre-Administration of PLX-R18 Cells Protects Mice from Radiation-Induced Hematopoietic Failure and Lethality—→152022A functional corona around extracellular vesicles enhances angiogenesis, skin regeneration and immunomodulation.Journal of extracellular vesicles→162021RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe-Why the European Union Should Invest More!Frontiers in medicine→172021Perinatal Cells: A Promising COVID-19 Therapy?—→182020Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019.Critical care explorations→192020Perinatal Cells: A Promising COVID-19 Therapy?Frontiers in bioengineering and biotechnology→202020Mesenchymal Stromal Cells from Fetal and Maternal Placenta Possess Key Similarities and Differences: Potential Implications for Their Applications in Regenerative Medicine.Cells→212019PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery→222018Rescue from lethal acute radiation syndrome (ARS) with severe weight loss by secretome of intramuscularly injected human placental stromal cells.Journal of cachexia, sarcopenia and muscle→232018Human Placental-Derived Adherent Stromal Cells Co-Induced with TNF-α and IFN-γ Inhibit Triple-Negative Breast Cancer in Nude Mouse Xenograft Models.Scientific reports→242017Placenta-Derived Adherent Stromal Cells Improve Diabetes Mellitus-Associated Left Ventricular Diastolic Performance.Stem cells translational medicine→252017Placenta-derived PLX-PAD mesenchymal-like stromal cells are efficacious in rescuing blood flow in hind limb ischemia mouse model by a dose- and site-dependent mechanism of action.Cytotherapy→262015Concise Review: Process Development Considerations for Cell Therapy.Stem cells translational medicine→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Pluri Inc (prev Pluristem)

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.